Friday, July 25, 2008

CROs are Profiting from the Increased Outsourcing of Drug Research and Development

MarketWatch reports that biopharmaceutical companies are increasingly seeking help from contract research organizations to save money on the expensive and time-consuming process of bringing new drugs to the market. This information comes from the latest Sector Focus Commentary by health care analysts at Turner Investment Partners. .

The analysts observed that the FDA has created stricter guidelines on safety and have diminished tolerance for side effects. This in turn will make it harder for new drugs to come into the market. Instead of building laboratories within their own facilities, pharma companies will be passing on research responsibilities over to CROs in an attempt to reduce expenses.

No comments:

Post a Comment